Amphista Therapeutics

Amphista Therapeutics is a Cambridge, UK targeted protein degradation company whose Targeted Glue degraders deploy E3 ligases beyond cereblon, such as DCAF16, chosen for each target. Its lead programme, AMX-883, is an orally bioavailable, selective DCAF16-mediated BRD9 degrader for acute myeloid leukaemia that releases the differentiation block in a broad AML population, shows in vivo efficacy alone and synergy with venetoclax, and received FDA clearance of its IND application in June 2026 as the first BRD9-targeted therapy for AML. An oral SMARCA2 Targeted Glue degrader targets SMARCA4-deficient tumours including non-small cell lung cancer through synthetic lethality, and a pan-TEAD degrader targets Hippo pathway-driven cancers such as mesothelioma and NSCLC; both are preclinical, with data presented at AACR 2026. The company is registered in England and Wales (number 11119959) with its head office at Granta Park, Great Abington, Cambridge.